Clinical characteristics of Parkinson's disease in the outpatient clinic of a regional hospital in Peru
DOI:
https://doi.org/10.17843/rpmesp.2025.424.15105Keywords:
Parkinson´s Disease, Cognitive Dysfunction, Depression, AnxietyAbstract
Parkinson's Disease (PD) is the fastest-growing neurodegenerative disorder worldwide. The clinical characteristics of adults with PD in a regional referral hospital in Arequipa were determined through a descriptive and cross-sectional study conducted between June 2023 and January 2025. Sixty adults with PD were included (20 women), and the average age was 64.4 years. The most frequent motor phenotype was the tremor-dominant type (73.3%). All received tablets with 250 mg of levodopa and 25 mg of carbidopa. Half took between 250 and 750 mg of levodopa daily, and 21% presented with dyskinesias. The most frequent non-motor symptoms were anxiety (93.2%), depression (88.6%), and mild cognitive impairment (>60%). These findings highlight the opportunity to optimize the treatment of motor and non-motor symptoms with pharmacological and non-pharmacological therapies focused on improving the quality of life of PD patients residing in the Arequipa region.
Downloads
References
Kalia LV, Lang AE. Parkinson’s disease. Lancet. 2015;386(9996):896-912. doi: 10.1016/S0140-6736(14)61393-3.
Tolosa E, Garrido A, Scholz SW, Poewe W. Challenges in the diagnosis of Parkinson’s disease. Lancet Neurol. 2021;20(5):385-97. doi:
1016/S1474-4422(21)00030-2.
Tysnes OB, Storstein A. Epidemiology of Parkinson’s disease. J Neural Transm (Vienna). 2017;124(8):901-5. doi: 10.1007/s00702-017-1686-y.
Condor IR, Atencio-Paulino JI, Contreras-Cordova CR. Características clínico epidemiológicas de la enfermedad de parkinson en un hospital nacional de la sierra peruana. Rev Fac Med Hum. 2019;19(4):14-21. doi: 10.25176/rfmh.v19i4.2342.
Cosentino C, Nuñez Y, Torres L. Frequency of non-motor symptoms in Peruvian patients with Parkinson’s disease. Arq Neuropsiquiatr.
;71(4):216-9. doi: 10.1590/0004-282X20130005.
Lizarraga KJ, Zizzi C, Chunga N, Quispe Moore LM, Risco J, Valdovinos B, et al. Cross-cultural learning during an international exchange
program in medical education: a qualitative study. BMC Med Educ. 2025;25(1):1217. doi: 10.1186/s12909-025-07763-x.
Lizárraga KJ, Salazar IC, Zizzi C, Romero S, Arispe JC, Quico AV, et al. Locally adapting digital health technologies to address the global
challenge of Parkinson’s disease. Equity Neurosci. 2025;1(2):100010. doi: 10.1016/j.neuros.2025.100010.
Centeno J, Espejo I, Flor M, Astete Y, Palacios S, Camargo I, et al. Biperiden for dopaminergic-resistant tremor in people living with Parkinson’s disease in a low-resource setting: A single-center case series. 5th Pan American Parkinson’s Disease and Movement Disorders Congress (Abstract #61) Cartagena, Colombia. 2024. doi: 10.1002/mdc3.13966.
Corcoran J, Powell S, Flor M, Astete Y, Camargo I, Lizarraga KJ. Abnormal Movements of the Back Heralding Amyotrophic Lateral Sclerosis. Mov Disord Clin Pract. 2021;8(5):788-90. doi: 10.1002/mdc3.13215.
Fung C, Maxwell N, Powell S, Benassai M, Chunga N, Corcoran J, et al. Virtual Adaptation of an International Exchange Program in Medical Education. Ann Glob Health. 2022;88(1):52. doi: 10.5334/aogh.3663.
Hughes AJ, Daniel SE, Kilford L, Lees AJ. Accuracy of clinical diagnosis of idiopathic Parkinson’s disease: a clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry. 1992;55(3):181-4. doi: 10.1136/jnnp.55.3.181.
Delgado C, Araneda Yañez A, Behrens MI. Validación del instrumento Montreal Cognitive Assessment en español en adultos mayores de 60 años. Neurologia (Engl Ed). 2019;34(6):376-385. doi: 10.1016/j.nrl.2017.01.013.
Wang J, Cheng N, Yao Z, Liu J, Kan X, Hui Z, et al. Early-onset Parkinson’s disease, regional and national burden, and its attributable risk factors in 204 countries and regions from 1990 to 2021: Results from the global burden of disease study 2021. Parkinsonism Relat Disord. 2025;134:107778. doi: 10.1016/j.parkreldis.2025.107778.
Ahlskog JE, Muenter MD. Frequency of levodopa-related dyskinesias and motor fluctuations as estimated from the cumulative literature. Mov Disord. 2001;16(3):448-58. doi: 10.1002/mds.1090.
Kaakkola S, Männistö PT, Nissinen E, Vuorela A, Mäntylä R. The effect of an increased ratio of carbidopa to levodopa on the pharmacokinetics of levodopa. Acta Neurol Scand. 1985;72(4):385-91. doi: 10.1111/j.1600-0404.1985.tb00888.x.
Titova N, Levin O, Katunina E, Ray Chaudhuri K. ‘Levodopa Phobia’: a review of a not uncommon and consequential phenomenon. NPJ
Parkinsons Dis. 2018;4:31. doi: 10.1038/s41531-018-0067-z.
Frequin HL, Verschuur CVM, Suwijn SR, Boel JA, Post B, Bloem BR, et al. Long-Term Follow-Up of the LEAP Study: Early Versus Delayed
Levodopa in Early Parkinson’s Disease. Mov Disord. 2024;39(6):975-82. doi: 10.1002/mds.29796.
Rodríguez-Violante M, Villar-Velarde A, Valencia-Ramos C, Cervantes-Arriaga A. Características epidemiológicas de pacientes con
enfermedad de Parkinson de un hospital de referencia en México. Arch Neurocien. 2011;16(2):64-68.
Rodriguez-Violante M, Cervantes-Arriaga A, Morales-Briceño H, Neri-Nani GA, Estrada-Bellmann I, Millán-Cepeda MR, et al. Estudio multicéntrico de evaluación de la sintomatología no motora a través de la Escala unificada de la enfermedad de Parkinson de la Sociedad de Trastornos del Movimiento (MDS-UPDRS). Rev Mex Neuroci. 2014;15(4):201-206.
Nie K, Gao Y, Mei M, Guo M, Huang Z, Wang L, et al. The clinical characteristics and cognitive features of mild cognitive impairment in
Parkinson’s disease and the analysis of relevant factors. J Clin Neurosci. 2019;63:142-8. doi: 10.1016/j.jocn.2019.01.021.
Downloads
Published
Issue
Section
License
Copyright (c) 2025 José J. Centeno-Arispe, Carlos A. Hurtado-González, Alan P. Murillo-Salas, Isabel P. Camargo-Salazar, Karlo J. Lizarraga-Mendoza
This work is licensed under a Creative Commons Attribution 4.0 International License.
How to Cite
